Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for large-scale genetic analysis, specifically utilizing proprietary BeadArray technology. The company focuses on SNP genotyping, gene expression profiling, and proteomics. Revenue is currently derived primarily from government grants, custom oligonucleotide sales, and SNP genotyping services. A strategic partnership with Applied Biosystems is central to the commercialization of their core technology, with product launches expected in mid-2002.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Total Revenue | $1,269 | $564 |
| Net Loss | $(8,667) | $(4,918) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.17) |
| Cash and Cash Equivalents | $10,417 | $113,599 |
| Total Investments (Available for Sale) | $77,363 | $89,621 |
| Total Assets | $140,552 | $122,465 |
| Long-Term Debt | $25,619 | $0 |
| Accumulated Deficit | $(58,800) | N/A |
Note: Q1 2001 data corresponds to the three months ended April 1, 2001.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 125% to $1.3 million, driven by a rise in product and service revenue from $28,000 to $540,000. However, research revenue (grants) decreased slightly from $536,000 to $729,000 (Note: Text states grants were 57% of revenue in 2002 vs 95% in 2001, indicating a shift in mix despite the absolute increase in research revenue line item).
- Operating Expenses: Total operating expenses rose 42% to $10.3 million. Research and Development (R&D) expenses increased $2.6 million to $7.1 million due to higher headcount and supply costs for BeadArray development. General and Administrative (G&A) expenses increased $0.4 million to $1.6 million.
- Debt Assumption: The company assumed a $26.0 million, 10-year mortgage in January 2002 to purchase its new facility. This resulted in a significant increase in interest expense to $0.6 million for the quarter, compared to $36,000 in the prior year.
- Cash Position: While cash and cash equivalents decreased significantly from the prior year's high levels, the company maintained a strong liquidity position with approximately $87.8 million in cash, cash equivalents, and investments combined.
- Capital Expenditures: Purchases of property and equipment surged to $24.3 million, primarily due to the acquisition of the new corporate facility.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring substantial and increasing operating losses as they scale R&D and build sales infrastructure. They anticipate needing significant revenue growth to achieve profitability. Current capital resources are expected to fund operations for at least the next 24 months.
- Commercialization: The company expects Applied Biosystems to commercialize the first collaboration products (SNP genotyping system) in mid-2002. Success is heavily dependent on this partnership.
- Risks:
- Profitability: No guarantee of achieving or maintaining profitability; accumulated deficit is $58.8 million.
- Manufacturing: Limited manufacturing experience; reliance on single sources for critical components (e.g., fiber optic bundles).
- Partnership Dependency: Lack of control over Applied Biosystems' development and marketing efforts.
- Market Acceptance: Target markets for genetic analysis are emerging and unproven; technology is new and faces competition.
- Legal: A lawsuit filed by a former employee (Anthony W. Czarnik) regarding employment termination is set for trial in Q2 2002.
Investor Verification Checklist
- Verify the timeline and progress of the Applied Biosystems partnership and the mid-2002 product launch.
- Monitor the burn rate of cash and the sufficiency of the $87.8 million liquidity position against rising R&D and facility costs.
- Assess the impact of the new $26 million mortgage on future interest expenses and cash flow.
- Review the status of the pending litigation with Anthony W. Czarnik.
- Track the transition of revenue mix from government grants to commercial product and service sales.